nach oben

Journal of Neurology

Erschienen in:

13.06.2019 | Review

Psychiatric disorders in multiple sclerosis

verfasst von: Maddalena Sparaco, Luigi Lavorgna, Simona Bonavita

Erschienen in: Journal of Neurology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Multiple sclerosis (MS) is characterized by a large spectrum of symptoms, involving all functional systems. Psychiatric symptoms are common in people with MS (pwMS) having an important impact on quality of life and on some features of MS (fatigue, sleep, disability, adherence to disease-modifying drugs). The main psychiatric disturbances in MS are depressive, bipolar, anxiety, schizophrenic and obsessive–compulsive syndromes.

Methods

Literature search for original articles and review in the databases, including PubMed and Scopus from 1959 to 2019.

Results and conclusion

Studies answering the aim of this review were selected and reported. Epidemiological and clinical aspects of psychiatric syndromes (PS) in MS as well as self-report diagnostic scales and radiological correlates of PS in MS are described. Moreover, some radiological studies about primary psychiatric disorders (PD) are reported to underline how gray matter atrophy, white matter abnormalities and corpus callosum involvement in these diseases, as features in common with MS, may explain the more frequent occurrence of PD in MS than in the general population.

Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517PubMed

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452PubMed

Charcot J-M (1877) Lectures on the diseases of the nervous system, delivered at La Salpetriere. New Sydenham Society, London, pp 194–195

Boerner RJ, Kapfhammer HP (1999) Psychopathological changes and cognitive impairment in encephalomyelitis disseminata. Eur Arch Psychiatry Clin Neurosci 249(2):96–102PubMed

Marrie RA, Walld R, Bolton JM et al (2017) Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. BMC Res Notes 10:619PubMedPubMedCentral

Tsivgoulis G, Triantafyllou N, Papageorgiou C et al (2007) Associations of the Expanded Disability Status Scale with anxiety and depression in multiple sclerosis outpatients. Acta Neurol Scand. 115(1):67–72PubMed

José Sá M (2008) Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg. 110(9):868–877

Beckner V, Howard I, Vella L et al (2010) Telephone-administered psychotherapy for depression in MS patients: moderating role of social support. J Behav Med. 33(1):47–59PubMed

Schippling S, O'Connor P, Knappertz V et al (2016) Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol 263(7):1418–1426PubMedPubMedCentral

10.

Gasim M, Bernstein CN, Graff LA et al (2018) Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: a systematic review. Mult Scler Relat Disord 26:124–156PubMed

11.

Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904PubMed

12.

Patten SB, Metz LM (2001) Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 7(4):243–248PubMed

13.

Feinstein A, O'Connor P, Feinstein K (2002) Multiple sclerosis, interferon beta-1b and depression. A prospective investigation. J Neurol 249(7):815–820PubMed

14.

Turner AP, Williams RM, Sloan AP et al (2009) Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Re-habil Psychol 54(1):116–121

15.

Di Matteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for non compliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160(14):2101–2107

16.

Mohr DC, Goodkin DE, Likosky W et al (1997) Treatment of depression improves adherence to interferon Beta-1b therapy for multiple sclerosis. Arch Neurol 54:531–533PubMed

17.

Lobentanz IS, Asenbaum S, Vass K et al (2004) Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 110(1):6–13PubMed

18.

Fruehwald S, Loeffler-Stastka H, Eher R et al (2001) Depression and quality of life in multiple sclerosis. Acta Neurol Sci 104(5):257–261

19.

Brown RF, Valpiani EM, Tennant CC et al (2009) Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother 82(Part1):41–56PubMed

20.

Marrie RA, Reingold S, Cohen J et al (2015) The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler 21(3):305–317PubMedPubMedCentral

21.

Bombardier CH, Blake KD, Ehde DM et al (2004) Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler 10:35–40PubMed

22.

Goretti B, Portaccio E, Ghezzi A et al (2010) Psychosocial issue in children and adolescents with multiple sclerosis. Neurol Sci 31:467–470PubMed

23.

Boeschoten RE, Braamse AMJ, Beekman ATF (2017) Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 372:331–341PubMed

24.

Marrie RA, Fisk JD, Yu BN et al (2013) Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol 13:16PubMedPubMedCentral

25.

Beck AT, Steer RA, Brown GA (1996) Beck depression inventory-II (BDI-II) manual. Pearson, Oxford

26.

Nyenhuis DL, Rao S, Zajecka JM et al (1995) Mood disturbance versus other symptoms of depression in multiple sclerosis. J Int Neuropsychol Soc 1:291–296PubMed

27.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMed

28.

Radloff LS (1977) The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401

29.

Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire. JAMA 282(18):1737–1744PubMed

30.

Cella D, Yount S, Rothrock N et al (2007) The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care 45(5 Suppl 1):S3–S11PubMedPubMedCentral

31.

DeWalt DA, Rothrock N, Yount S et al (2007) Evaluation of item candidates: the PROMIS qualitative item review. Med Care 45(5 Suppl 1):S12–S21PubMedPubMedCentral

32.

Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62PubMedPubMedCentral

33.

Quaranta D, Marra C, Zinno M et al (2012) Presentation and validation of the multiple sclerosis depression rating scale: a test specifically devised to investigate affective disorders in multiple sclerosis patients. Clin Neuropsychol 26(4):571–587PubMed

34.

Sullivan MJ, Weinshenker B, Mikail S et al (1995) Screening for major depression in the early stages of multiple sclerosis. Can J Neurol Sci 22:228–231PubMed

35.

Nyenhuis DL, Luchetta T, Yamamoto C et al (1998) The development, standardization, and initial validation of the Chicago multiscale depression inventory. J Pers Assess 70(2):386–401PubMed

36.

Strober LB, Arnett PA (2015) Depression in multiple sclerosis: the utility of common self-report instruments and development of a disease-specific measure. J Clin Exp Neuropsychol 37(7):722–732PubMed

37.

Nicholl CR, Lincoln NB, Francis VM et al (2001) Assessment of emotional problems in people with multiple sclerosis. Clin Rehabil 15(6):657–668PubMed

38.

Honarmand K, Feinstein A (2009) Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler 15(12):1518–1524PubMed

39.

Verdier-Taillefer MH, Gourlet V, Fuhrer R et al (2001) Psychometric properties of the Center for Epidemiologic Studies-Depression scale in multiple sclerosis. Neuroepidemiology 20(4):262–267PubMed

40.

Andresen EM, Malmgren JA, Carter WB et al (1994) Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med 10(2):77–84PubMed

41.

Kroenke K, Spitzer RL, Williams JBW (2001) The PHQ-9 validity of a brief depression severity measure. J Gen Intern Med 16(9):606–613PubMedPubMedCentral

42.

Kroenke K, Spitzer RL, Williams JBW (2003) The patient health questionnaire-2: validity of a two-item depression screener. Med Care 41(11):1284–1292PubMed

43.

Raimo S, Troiano L, Spitaleri D et al (2015) Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis. Qual Life Res 24(8):1973–1980PubMed

44.

Amtmann D, Kim J, Chung H (2014) Comparing CESD-10, PHQ-9, and PROMIS depression instruments in individuals with multiple sclerosis. Rehabil Psychol 59(2):220–229. https://doi.org/10.1037/a0035919CrossRefPubMedPubMedCentral

45.

Jones KH, Ford DV, Jones PA et al (2012) A large-scale study of anxiety and depression in people with multiple sclerosis: a survey via the web portal of the UK MS Register. PLoS ONE 7(7):e41910. https://doi.org/10.1371/journal.pone.0041910CrossRefPubMedPubMedCentral

46.

Julian L, Merluzzi NM, Mohr DC (2007) The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis. Mult Scler 13(1):81–86PubMed

47.

Wilken JA, Sullivan C (2007) Recognizing and treating common psychiatric disorders in multiple sclerosis. Neurologist 13(6):343–354PubMed

48.

Mohr DC, Hart SL, Goldberg A (2003) Effects of treatment for depression on fatigue in multiple sclerosis. Psychosom Med 65(4):542–547PubMed

49.

Hart S, Fonareva I, Merluzzi N et al (2005) Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res 14(3):695–703PubMed

50.

Vitkova M, Gdovinova Z, Rosenberger J et al (2014) Factors associated with poor sleep quality in patients with multiple sclerosis differ by disease duration. Disabil. Health J 7(4):466–471PubMed

51.

Jones KH, Jones PA, Middleton RM et al (2014) Physical disability, anxiety and depression in people with MS: an internet-based survey via the UK. MS Register. PLoS ONE 9(8):e104604PubMedPubMedCentral

52.

Bakshi R, Shaikh ZA, Miletich RS et al (2000) Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 6(3):181–185PubMed

53.

Amato MP, Ponziani G, Rossi F et al (2001) Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 7(5):340–344PubMed

54.

Marrie RA, Patten SB, Berrigan LI et al (2018) Diagnoses of depression and anxiety versus current symptoms and quality of life in multiple sclerosis. Int J MS Care 20(2):76–84PubMedPubMedCentral

55.

Julian LJ (2011) Cognitive functioning in multiple sclerosis. Neurol Clin 29:507–525PubMed

56.

Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151PubMed

57.

Arnett PA, Higginson CI, Voss WD et al (1999) Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 13:546–556PubMed

58.

Arnett PA, Higginson CI, Voss WD et al (1999) Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology 13:434–446PubMed

59.

Arnett PA, Higginson CI, Randolph JJ (2001) Depression in multiple sclerosis: relationship to planning ability. J Int Neuropsychol Soc 7:665–674PubMed

60.

Diamond BJ, Johnson SK, Kaufman M et al (2008) Relationships between information processing, depression, fatigue and cognition in multiple sclerosis. Arch Clin Neuropsychol 23(2):189–199PubMed

61.

Scalfari A, Knappertz V, Cutter G et al (2013) Mortality in patients with multiple sclerosis. Neurology 81(2):184–192PubMedPubMedCentral

62.

Manouchehrinia A, Tanasescu R, Tench CRJ et al (2016) Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. Neurol Neurosurg Psychiatry 87(3):324–331

63.

Brenner P, Burkill S, Jokinen J et al (2016) Multiple sclerosis and risk of attempted and completed suicide—a cohort study. Eur J Neurol 23(8):1329–1336PubMed

64.

Jefferies K (2006) The neuropsychiatry of multiple sclerosis. Adv Psychiatr Treat 12:214–220

65.

Feinstein A (2002) An examination of suicidal intent in patients with multiple sclerosis. Neurology 59:674–678PubMed

66.

Turner AP, Williams RM, Bowen JD et al (2006) Suicidal ideation in multiple sclerosis. Arch Phys Med Rehabil 87(8):1073–1078PubMed

67.

Strupp J, Ehmann C, Galushko M et al (2016) Risk factors for suicidal ideation in patients feeling severely affected by multiple sclerosis. J Palliat Med 19(5):523–528PubMed

68.

Bonavita S, Tedeschi G, Gallo A (2013) Morphostructural MRI abnormalities related to neuropsychiatric disorders associated to multiple sclerosis. Mult Scler Int 2013:102454PubMedPubMedCentral

69.

Pujol J, Bello J, Deus J et al (1997) Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 49(4):1105–1110PubMed

70.

Feinstein A, Roy P, Lobaugh N et al (2004) Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62(4):586–590PubMed

71.

Bakshi R, Czarnecki D, Shaikh ZA et al (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. NeuroReport 11(6):1153–1158PubMed

72.

Zorzon M, de Masi R, Nasuelli D et al (2001) Depressiosn and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 248(5):416–421PubMed

73.

Di Legge S, Piattella MC, Pozzilli C et al (2003) Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis. Mult Scler 9:302–306PubMed

74.

Feinstein A, O’Connor P, Akbar N et al (2010) Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler 16(2):189–196PubMed

75.

Bonavita S, Sacco R, Esposito S et al (2017) Default mode network changes in multiple sclerosis: a link between depression and cognitive impairment? Eur J Neurol 24(1):27–36PubMed

76.

Rocca MA, Pravatà E, Valsasin P et al (2015) Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. Hum Brain Mapp 36(12):5051–5063PubMedPubMedCentral

77.

Pravatà E, Rocca MA, Valsasina P et al (2017) Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. Mult Scler 23(14):1864–1874PubMed

78.

van Geest Q, Boeschoten RE, Keijzer MJ et al (2018) Fronto-limbic disconnection in patients with multiple sclerosis and depression. Mult Scler J 1:1352458518767051

79.

Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMed

80.

Beck AT, Steer RA (1990) Beck anxiety inventory (BAI) manual. Pearson, Oxford

81.

Spielberger CD, Gorsuch RL, Lushene RE (1970) Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto

82.

Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097PubMed

83.

Maier W, Buller R, Philipp M et al (1988) The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14(1):61–68PubMed

84.

Santangelo G, Sacco R, Siciliano M et al (2016) Anxiety in multiple sclerosis: psychometric properties of the state-trait anxiety inventory. Acta Neurol Scand. 134(6):458–466PubMed

85.

Terrill AL, Hartoonian N, Beier M et al (2015) The 7-item generalized anxiety disorder scale as a tool for measuring generalized anxiety in multiple sclerosis. Int J MS Care 17:49–56PubMedPubMedCentral

86.

Senders A, Hanes D, Bourdette D et al (2014) Reducing survey burden: Feasibility and validity of PROMIS measures in multiple sclerosis. Mult Scler 20(8):1102–1111PubMedPubMedCentral

87.

Marrie RA, Zhang L, Lix LM et al (2018) The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. Mult Scler Relat Disord 20:9–15. https://doi.org/10.1016/j.msard.2017.12.007CrossRefPubMed

88.

Hartoonian N, Terrill AL, Beier ML et al (2015) Predictors of anxiety in multiple sclerosis. Rehabil Psychol 60(1):91–98PubMed

89.

Marrie RA, Horwitz RI, Cutter G et al (2011) Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand 124:135–141PubMed

90.

Stenager E, Knudsen L, Jensen K (1994) Multiple sclerosis: correlation of anxiety, physical impairment and cognitive dysfunction. Italian J Neurol Sci 15:97–101

91.

Morrow SA, Rosehart H, Pantazopoulos K (2016) Anxiety and depressive symptoms are associated with worse performance on objective cognitive tests in MS. J Neuropsychiatry Clin Neurosci 28:118–123PubMed

92.

Julian LJ, Arnett PA (2009) Relationships among anxiety, depression, and executive functioning in multiple sclerosis. Clin Neuropsychol 23(794–804):16

93.

Goretti B, Viterbo RG, Portaccio E et al (2014) Anxiety state affects information processing speed in patients with multiple sclerosis. Neurol Sci 35:559–563PubMed

94.

Zhang Y, Li L, Yu R, Liu J, Tang J, Tan L et al (2013) White matter integrity alterations in first episode, treatment-naive generalized anxiety disorder. J Affect Disord 148:196–201. https://doi.org/10.1016/j.jad.2012.11.060CrossRefPubMed

95.

Zhang L, Zhang Y, Li L, Li Z, Li W, Ma N et al (2011) Different white matter abnormalities between the first-episode, treatment-naive patients with posttraumatic stress disorder and generalized anxiety disorder without comorbid conditions. J Affect Disord 133:294–299. https://doi.org/10.1016/j.jad.2011.03.040CrossRefPubMed

96.

Liao M, Yang F, Zhang Y, He Z, Su L, Li L (2014) White matter abnormalities in adolescents with generalized anxiety disorder: a diffusion tensor imaging study. BMC Psychiatry 14:41. https://doi.org/10.1186/1471-244X-14-41CrossRefPubMedPubMedCentral

97.

Wang W, Qian S, Liu K, Li B, Li M, Xin K et al (2016) Reduced white matter integrity and its correlation with clinical symptom in first-episode, treatment-naive generalized anxiety disorder. Behav Brain Res 314:159–164. https://doi.org/10.1016/j.bbr.2016.08.017CrossRefPubMed

98.

Etkin A, Prater KE, Schatzberg AF et al (2009) Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry 66:1361–1372. https://doi.org/10.1001/archgenpsychiatry.2009.104CrossRefPubMed

99.

Qiao J, Li A, Cao C et al (2017) Aberrant functional network connectivity as a biomarker of generalized anxiety disorder. Front Hum Neurosci 11:626. https://doi.org/10.3389/fnhum.2017.00626CrossRefPubMedPubMedCentral

100.

Sobanski T, Wagner G, Peikert G et al (2010) Temporal and right frontal lobe alterations in panic disorder: a quantitative volumetric and voxel-based morphometric MRI study. Psychol Med 40:1879–1886PubMed

101.

Asami T, Yamasue H, Hayano F et al (2009) Sexually dimorphic gray matter volume reduction in patients with panic disorder. Psychiatry Res 173:128–134PubMed

102.

Lai CH, Wu YT (2012) Fronto-temporo-insula gray matter alterations of first episode, drug-naive and very late-onset panic disorder patients. J Affect Disord 140:285–291PubMed

103.

Han DH, Renshaw PF, Dager SR, Chung A, Hwang J et al (2008) Altered cingulate white matter connectivity in panic disorder patients. J Psychiatr Res 42:399–407PubMed

104.

Lai CH, Wu YT (2013) Fronto-occipital fasciculus, corpus callosum and superior longitudinal fasciculus tract alterations of first-episode, medication-naive and late-onset panic disorder patients. J Affect Disord 146:378–382PubMed

105.

Kim B, Kim JH, Kim MK et al (2014s) Frontal white matter alterations in short-term medicated panic disorder patients without comorbid conditions: a diffusion tensor imaging study. PLoS ONE 9(4):e95279PubMedPubMedCentral

106.

Hirschfeld RM, Williams JB, Spitzer RL et al (2000) Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 157(11):1873–1875PubMed

107.

Hirschfeld RM, Holzer C, Calabrese JR et al (2003) Validity of the mood disorder questionnaire: a general population study. Am J Psychiatry 160(1):178–180PubMed

108.

Angst J, Adolfsson R, Benazzi F et al (2005) The HCL-32: a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 88:217–233PubMed

109.

Carvalho AF, Takwoingi Y, Sales PM et al (2015) Screening for bipolar spectrumdisorders: a comprehensive meta-analysis of accuracy studies. J Affect Disord 172:337–346PubMed

110.

Takwoingi Y, Riley RD, Deeks JJ (2015) Meta-analysis of diagnostic accuracy studies in mental health. Evid Based Ment Health 18(4):103–109PubMedPubMedCentral

111.

Eaton WW, Pedersen MG, Nielsen PR et al (2010) Autoimmune diseases, bipolar disorder, and nonaffective psychosis. Bipolar Disord 12:638–646PubMedPubMedCentral

112.

Joffe RT, Lippert GP, Gray TA et al (1987) Personal and family history of affective illness in patients with multiple sclerosis. J Affect Disord 12:63–65PubMed

113.

Carta MG, Moro MF, Lorefice L et al (2014) The risk of bipolar disorders in multiple sclerosis. J Affect Disord 155:255–260PubMed

114.

Andreazza AC, Cassini C, Rosa AR et al (2007) Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 41:523–529PubMed

115.

Zarate CA Jr, Singh J, Manji HK (2006) Cellular plasticity cascades: targets for thedevelopment of novel therapeutics for bipolar disorder. Biol Psychiatry 59:1006–1020PubMed

116.

Bozikas VP, Anagnostouli MC, Petrikis P et al (2003) Familial bipolar disorder and multiple sclerosis: a three-generation HLA family study. Progress Neuropsychopharmacol Biol Psychiatry 27(5):835–839

117.

Kosmidis MH, Bozikas VP, Giannouli V et al (2012) Familial comorbidity of bipolar disorder and multiple sclerosis: genetic susceptibility, coexistence or causal relationship? Behav Neurol 25(4):341–349PubMedPubMedCentral

118.

Schiffer RB, Weitkamp LR, Wineman NM et al (1988) Multiple sclerosis and affective disorder. Family history, sex, and HLA-DR antigens. Arch Neurol 45(12):1345–1348PubMed

119.

Bhangle SD, Kramer N, Rosenstein ED (2013) Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int 33:1923–1932PubMed

120.

Lorefice L, Fenu G, Fois M et al (2018) Pulse steroid therapy in multiple sclerosis and mood changes: an exploratory prospective study. Mult Scler Relat Disord 20:104–108PubMed

121.

Geoffroy PA, Auffret M, Deheul S et al (2014) Baclofen-induced manic symptoms: case report and systematic review. Psychosomatics 55(4):326–332PubMed

122.

Haarman BC, Riemersma-Van der Lek RF, de Groot JC et al (2014) Neuroinflammation in bipolar disorder-A [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun 40:219–225PubMed

123.

Rao JS, Harry GJ, Rapoport SI et al (2010) Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 15(4):384–392PubMed

124.

Altshuler LL, Curran JG, Houser P et al (1995) T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. Am J Psychiatry 152:1139–1144PubMed

125.

Lloyd AJ, Moore PB, Cousins DA et al (2009) White matter lesions in euthymic patients with bipolar disorder. Acta Psychiatr Scand 120(6):481–491PubMed

126.

Beyer JL, Young R, Kuchibhatla M, Krishnan KR et al (2009) Hyperintense MRI lesions in bipolar disorder: a meta-analysis and review. Int Rev Psychiatry 21(4):394–409PubMedPubMedCentral

127.

Bruno S, Cercignani M, Ron MA (2008) White matter abnormalities in bipolar disorder: a voxel-based diffusion tensor imaging study. Bipolar Disord 10(4):460–468PubMed

128.

Bruno SD, Barker GJ, Cercignani M et al (2004) A study of bipolar disorder using magnetization transfer imaging and voxel-based morphometry. Brain 127(11):2433–2440PubMed

129.

Lagopoulos J, Hermens DF, Hatton SN et al (2013) Microstructural white matter changes in the corpus callosum of young people with bipolar disorder: a diffusion tensor imaging study. PLoS ONE 8(3):e59108PubMedPubMedCentral

130.

Piaggio N, Schiavi S, Martino M et al (2018) Exploring mania-associated white matter injury by comparison with multiple sclerosis: a diffusion tensor imaging study. Psychiatry Res Neuroimaging 281:78–84PubMed

131.

Arneth BM (2017) Multiple sclerosis and schizophrenia. Int J Mol Sci 18(8):1760PubMedCentral

132.

Müller N, Schwarz MJ (2010) Immune system and schizophrenia. Curr Immunol Rev 6(3):213–220PubMedPubMedCentral

133.

Feinstein A, du Boulay G, Ron MA (1992) Psychotic illness in multiple sclerosis: a clinical and magnetic resonance imaging study. Br J Psychiatry 161:680–685PubMed

134.

Bora E, Fornito A, Radua J, et al. (2011) Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and ******meta-regression analysis. Schizophr Res.

135.

Bagary MS, Symms MR, Barker GJ et al (2003) Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch Gen Psychiatry 60(8):779–788PubMed

136.

Watson DR, Anderson JM, Bai F et al (2012) A voxel based morphometry study investigating brain structural changes in first episode psychosis. Behav Brain Res 227:91–99PubMed

137.

Joo SW, Yoon W, Shon SH et al (2018) Altered white matter connectivity in patients with schizophrenia: an investigation using public neuroimaging data from SchizConnect. PLoS ONE 13(10):e0205369PubMedPubMedCentral

138.

Hua J, Blair NIS, Paez A et al (2019) Altered functional connectivity between sub-regions in the thalasmus and cortex in schizophrenia patients measured by resting state BOLD fMRI at 7T. Schizophr Res 206:370–377PubMed

139.

Haroutunian V, Davis KL (2007) Introduction to the Special Section: Myelin and oligodendrocyte abnormalities in schizophrenia. Int J Neuropsychopharmacol 10:499–502PubMed

140.

Korostil M, Feinstein A (2007) Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 13(1):67–72PubMed

141.

Hoekstra P, Minderaa R (2005) Tic disorders and obsessive-compulsive disorder: Is autoimmunity involved? Int Rev Psychiatry 17(6):497–502PubMed

142.

Menzies L, Chamberlain SR, Laird AR et al (2008) Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 32(3):525–549PubMed

143.

Li F, Huang X, Yang Y et al (2011) Microstructural brain abnormalities in patients with obsessive-compulsive disorder: diffusion-tensor MR imaging study at 3.0 T. Radiology 260(1):216–223PubMed

144.

Oh JS, Jang JH, Jung WH et al (2012) Reduced fronto-callosal fiber integrity in unmedicated patients with OCD: a diffusion tractography study. Hum Brain Mapp 33(10):2441–2452PubMed

145.

Radua J, Grau M, van den Heuvel OA et al (2014) Multimodal voxel-based meta-analysis of white matter abnormalities in obsessive-compulsive disorder. Neuropsychopharmacology 39(7):1547–1557PubMedPubMedCentral

146.

Christopher JC, Lencz T, Robinson DG et al (2008) Gray matter structural alterations in obsessive–compulsive disorder: relationship to neuropsychological functions. Psychiatry Res 164(2):123–131

147.

Diwadkar VA, Burgess A, Hong E et al (2015) Dysfunctional activation and brain network profiles in youth with obsessive-compulsive disorder: a focus on the dorsal anterior cingulate during working memory. Front Hum Neurosci 9:149PubMedPubMedCentral

148.

Boedhoe PSW, Schmaal L, Abe Y et al (2018) Cortical abnormalities associated with pediatric and adult obsessive-compulsive disorder: findings from the ENIGMA obsessive–compulsive disorder working group. Am J Psychiatry 175(5):453–462PubMed

149.

Tinelli E, Francia A, Quartuccio EM et al (2013) Structural brain MR imaging changes associated with obsessive-compulsive disorder in patients with multiple sclerosis. Am J Neuroradiol 34(2):305–309PubMedPubMedCentral

150.

Özkan A, Altinbaş K, Koç ER et al (2016) Affective temperament profiles in patients with multiple sclerosis: association with mood disorders. Noro Psikiyatr Ars 53(4):311–316PubMed

151.

Rihmer Z, Akiskal KK, Rihmer A et al (2010) Current research on affective temperaments. Curr Opin Psychiatry 23:12–18PubMed

Titel: Psychiatric disorders in multiple sclerosis
verfasst von: Maddalena Sparaco
Luigi Lavorgna
Simona Bonavita
Publikationsdatum: 13.06.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 1/2021
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09426-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results and conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Not only pulmonary rehabilitation for critically ill patients with COVID-19

Impaired naming performance in temporal lobe epilepsy: language fMRI responses are modulated by disease characteristics

Presentation outside office hours does not negatively influence treatment times for reperfusion therapy for acute ischemic stroke

The European Physiotherapy Guideline for Parkinson’s Disease: translation for non-English speaking countries

Symptomatic isolated internal carotid artery occlusion with initial medical management: a monocentric cohort